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Abstract
Control of virus replication in HIV-1 infection is critical to delaying disease progression. While cellular immune responses are
a key determinant of control, relatively little is known about the contribution of the infecting virus to this process. To gain
insight into this interplay between virus and host in viral control, we conducted a detailed analysis of two heterosexual HIV-
1 subtype A transmission pairs in which female recipients sharing three HLA class I alleles exhibited contrasting clinical
outcomes: R880F controlled virus replication while R463F experienced high viral loads and rapid disease progression. Near
full-length single genome amplification defined the infecting transmitted/founder (T/F) virus proteome and subsequent
sequence evolution over the first year of infection for both acutely infected recipients. T/F virus replicative capacities were
compared in vitro, while the development of the earliest cellular immune response was defined using autologous virus
sequence-based peptides. The R880F T/F virus replicated significantly slower in vitro than that transmitted to R463F. While
neutralizing antibody responses were similar in both subjects, during acute infection R880F mounted a broad T cell
response, the most dominant components of which targeted epitopes from which escape was limited. In contrast, the
primary HIV-specific T cell response in R463F was focused on just two epitopes, one of which rapidly escaped. This
comprehensive study highlights both the importance of the contribution of the lower replication capacity of the
transmitted/founder virus and an associated induction of a broad primary HIV-specific T cell response, which was not
undermined by rapid epitope escape, to long-term viral control in HIV-1 infection. It underscores the importance of the
earliest CD8 T cell response targeting regions of the virus proteome that cannot mutate without a high fitness cost, further
emphasizing the need for vaccines that elicit a breadth of T cell responses to conserved viral epitopes.
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Introduction
In the absence of antiretroviral therapy (ART) there is
significant variation in the clinical outcome of HIV-1 infection
[1]. Most untreated patients exhibit persistent viral replication that
is detectable in plasma, and experience a gradual decline in CD4
T cells. A majority of chronically-infected, untreated individuals
eventually reach CD4 T cell counts of ,200 cells/ml and develop
the opportunistic infections that define AIDS [2]. Some HIV-1
infected individuals progress to CD4 T cell counts of,200 cells/ml
in 3–4 years (rapid progressors, [2,3]) while a small proportion (5–
15%) are slow progressors, remaining disease free for .12 years
[4–7]. A subset of the slow progressors becomes long-term non-
progressors (LTNP), remaining disease free for even longer [5,8].
Less than 1% of HIV-1 infected individuals spontaneously control
disease progression by durably suppressing plasma viral load (VL)
to levels undetectable with standard assays (elite controllers (EC);
VL,50 RNA copies/ml) [2,5,9,10]. Recent studies on ECs have
defined critical roles for host genetics, viral factors and de novo
host immune responses in controlling disease progression
[2,8,11,12].
Set-point VL is considered to be a critical indicator of the
trajectory for clinical disease [3,13,14], and we and others have
recently shown that this reflects a complex interplay between the
immunogenetics of the newly infected host and replication
capacity of the virus, which in turn can be molded by the immune
response of the transmitting partner [15–21]. Host immunogenet-
ics, especially HLA class I genotype, significantly influences disease
progression in the HIV-1 infected population and common genetic
variants can explain about 20% of viral control [22–24]. The
statistically significant association between protective HLA class I
alleles, such as B*57, B*27 and B*81, and their additive effect on
control of VL during acute and chronic infection has been shown
in multiple studies [19,21,25–28]. Indeed, HLA class I-restricted
HIV-specific CD8 T cell responses are the major force suppressing
viremia throughout infection [5,29,30]. Escape mutations that are
selected for in the replicating HIV quasispecies during infection
can abrogate the effects of epitope-specific CD8 T cell responses
[31–35]. However, mutations that confer escape from protective
HLA alleles can also result in a high fitness cost to the virus
[16,17,36,37]. Moreover, in HLA-B*57+ individuals, there is
evidence for continued recognition and suppression of virus with
mutated epitopes [38].
The phenotype of the transmitted/founder (T/F) virus also
appears to play a critical role in defining set-point VL [18,21,39–
41] and disease progression [18,42,43]. We previously demon-
strated an inverse correlation between the number of transmitted
CD8 T cell escape mutations in gag and the set-point VL in
newly-infected individuals [17]. Furthermore, transmitted HLA-
associated T cell escape mutations in Gag can decrease viral
replication capacity [16,18,20,36]. In studies of both chronically
and acutely infected EC, viruses exhibited reduced replicative
capacity that was linked to T cell driven escape mutations [44–46].
Moreover, the Env proteins of viruses from EC utilized CD4 and
CCR5 less efficiently and fused more slowly than Envs from
progressing individuals [47]. Nevertheless, replication-competent
virus can be recovered from some EC, suggesting that undetect-
able VL in these individuals is the result of immune control rather
than viral defects [44,48].
Our studies of HIV-1 transmission pairs in Zambia and
Rwanda have facilitated the analysis of virus populations in both
the transmitting source partner (donor partner) and the serocon-
verting partner (recipient partner), leading to an understanding of
the impact immune selection in the donor can have on the T/F
virus early in infection [18,21,49–51]. Recent technical advances
allow PCR amplification and sequencing of near full-length T/F
virus genomes and studies of immune selection on this initially
clonal population over time [52,53]. Moreover, knowledge of the
entire T/F virus proteome permits longitudinal analysis of cellular
and humoral immune responses to autologous peptides and virus
[54,55]. Use of these approaches enabled us to perform a
combined analysis of the fitness of the T/F virus and viral control
by host cellular and humoral responses, to better define the
interplay between these viral and host determinants in determin-
ing early virus control. We studied 2 HIV-1 subtype A
transmission pairs from a Rwandan cohort, in which the two
recipients shared 3/6 HLA class I alleles yet exhibited distinctly
different disease trajectories. One recipient rapidly progressed to a
CD4 count of ,350 cells/ml, while the other exhibited control of
the virus. To understand the basis for differences in rate of early
disease progression, we characterized near full-length viral genome
sequences longitudinally, defined the in vitro replication capacity
of the T/F virus populations, and delineated the nature and
magnitude of both the autologous virus-specific T cell and
neutralizing antibody (Ab) responses during the first year of
infection. Results from these studies reveal that infection with a T/
F virus with lower replication capacity, and the corresponding
induction of a broader HIV-specific CD8 T cell response targeting
more stable epitopes during primary infection were distinguishing
determinants of good control of virus replication.
Results
Transmission pairs
Two HIV-1 subtype A male to female virologically-linked
transmission pairs (R463 and R880) from a heterosexual
transmission cohort at Project San Francisco in Kigali, Rwanda
were studied. Both recipients were enrolled into the IAVI protocol
C early infection cohort at Fiebig stage IV for R463F and Fiebig
stage III for R880F (Table 1). PBMC were cryopreserved at Fiebig
stage V and IV respectively. R880F and R463F shared three HLA
class I alleles (B*1503, Cw*0210, and Cw*0602; Table 1). R880F
Author Summary
The length of time taken by HIV-1-infected individuals to
develop AIDS varies widely depending on how efficiently
virus replication is controlled. Although host cellular
immune responses are known to play an important role
in viral control, the contributions made by the infecting
virus and the host antibody response to this process are
less clear. To gain insight into this, we performed a
detailed analysis of the interplay between the infecting
virus and host immune responses in two HIV-1-infected
individuals, one of whom controlled virus replication
efficiently while the other did not. We found that the
virus infecting the HIV-1 controller replicated much less
well in culture than that infecting the progressor. The
antibody responses made by both subjects were similar,
but early after infection the controller mounted a T cell
response targeting many sites in the virus, whilst the
progressor’s T cell response initially targeted only two
sites, one of which rapidly mutated to avoid immune
recognition. This study highlights the contribution of the
replication capacity of the infecting virus and associated
early induction of a broad HIV-specific T cell response,
which was less readily undermined by rapid viral escape, to
viral control in HIV-1 infection.
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also possessed A*0201, A*0301 and B*4701 alleles, while R463F
possessed A*0101, A*3002 and B*4501 alleles. Interestingly, both
donor partners carried one protective allele; R880M B*5703 and
R463M B*8101, although only R880M exhibited a relatively low
VL (approximately 14,000 copies/ml) (Table 1).
CD4 T cell count and viral load trajectory
The highest plasma VL recorded during acute infection for
R463F (VL = 152,000,000 at Fiebig stage IV) was almost 400
times higher than that for R880F (VL = 430,843 at Fiebig stage
III) (Fig. 1A and 1B). Moreover, despite their similar HLA class I
alleles, R880F and R463F exhibited very different VL and CD4
count trajectories during the first year of infection (Fig. 1A and
1B). By 6 months post-enrollment, subject R880F’s VL had
dropped to an undetectable level (VL,49 copies/ml), and
remained at this level for the next 3 years of follow-up. R880F
plasma from the d157 time-point was confirmed to be negative for
ART. This elite controller had a CD4 count that averaged 580
cells/ml during the first year of infection (Fig. 1A). In contrast,
subject R463F exhibited a more rapid disease progression. The
set-point VL was around 400,000 copies/ml and the CD4 T cell
count dropped to 375 cells/ml during the first year of infection
(Fig. 1B). At 15 months post-infection, R463F initiated ART.
Amplification of full-length genomes and confirmation of
single virus initiation of systemic infection
Near full-length genome (NFLG; .9000 bp) viral sequences
were PCR amplified from the two HIV-1 transmission pairs.
These included viruses from the chronically infected donor’s viral
quasispecies near the time of transmission, and viruses from the
recipients at 5 different time-points (enrollment, month 2 or 3,
month 6, month 9, and 1 year). NFLG amplicons produced by
single genome PCR amplification (SGA) from patient PBMC and
plasma viral RNA were sequenced directly. At least 10 NFLG
sequences from each recipient were analyzed to establish the T/F
virus sequence, and neighbor-joining trees of donor and recipient
virus sequences confirmed that infection was initiated by a single
virus variant from the donor viral quasispecies in both cases (S1
Fig.).
Viral isolates generated from R880F and R463F in acute
infection exhibit different replication capacities in vitro
The peak VL during acute infection is likely strongly
influenced by the replicative fitness of the T/F virus in vivo.
To determine whether R880F was infected with a virus with
lower replication capacity (RC) than R463F, we generated virus
isolates from plasma of both recipients at the enrollment time-
point by growth in CD8 T cell-depleted primary PBMC from
HIV-seronegative donors. The RC of these viral isolates was
then compared in mixed donor, CD8 T cell-depleted, PBMC.
As shown in Fig. 2A, following infection at equal multiplicities
of infection, both R880F and R463F viral stocks (VS) were able
to replicate; however, the R463FVS replicated more rapidly
than the R880FVS (log10 slope 4.66/day vs 5.88/day), resulting
in a delay in detectable virus production for R880FVS. To
verify these observations, we also compared the in vitro RC of
infectious molecular clones (IMCs) corresponding to the
deduced T/F virus sequence from each subject (generated as
previously described [56]), obtaining very similar results
(Fig. 2B). We compared the relative growth of the two viruses
in 9 independent experiments, and calculated the growth rates
of each virus as the slope of increase in the logarithms of p24 or
RT activity over the times when this increase was linear. We
then used a Wilcoxon signed-rank test to compare the ratios of
slopes for the two viruses with the null hypothesis that both
viruses replicated at the same rate (i.e., ratio = 1). In each
experiment R463 replicated faster than R880, and overall there
was a statistically significant difference in the ratio of rates
(Fig. 2C; p = 0.0029).
Finally, to independently confirm this difference in replicative
capacity, we established a competition assay, in which CD8-
depleted, activated PBMC cultures were infected with both R880F
and R463F virus stocks, and the relative proportion of each virus
in the culture was monitored using a qPCR-based analysis over a
10-day infection period. As can be seen in Fig. 2D and S2 Fig.,
whether R463FVS was in an equal ratio to R880FVS, or in a 1:4
ratio, it rapidly outgrew the poorer replicating R880FVS. This
difference in RC in vitro is consistent with the VL differences
observed in these two acutely infected individuals in vivo (Fig. 1A
and 1B).
R880F was infected by a virus from a partner carrying the
B*5703 allele, and viral escape from CD8 T cell responses against
the major B*57 epitopes in Gag has been shown to decrease virus
replication [16,57,58]. Examination of the R880F T/F virus
sequence revealed escape mutations at four B*57 CD8 T cell
epitopes in p24 (ISW9, KF11, TW10 and QW9) (Fig. 2E).
Surprisingly, the R880F T/F virus lacked the serine to asparagine
change at position 165 in the KF11 Gag epitope that was present
in the majority (10/11) of the R880M amplicons (Fig. 2E). The
S165N change has been shown to compensate for the replication
Table 1. Transmission pair information.
Patient IDa Statusb
Virus
subtype
Fiebig
stagec
pVLd
copies/ml HLA class I alleles
R880M D A1 NA 13,929 A*0109 A*3303 B*4415 B*5703 Cw*0407 Cw*1701
R880F LR A1 III 430,843 A*0201 A*0301 B*1503 B*4701 Cw*0210 Cw*0602
R463M D A1 NA 108,624 A*0101 A*2301 B*4415 B*8101 Cw*0407 Cw*1801
R463F LR A1 IV 152,000,000 A*0101 A*3002 B*1503 B*4501 Cw*0210 Cw*0602
aM: male; F: female.
bD: donor, LR: virologically linked recipient.
cFiebig stage: Fiebig stage of the recipients at the time of enrollment into the IAVI protocol C early infection study, when plasma was first collected for viral sequence
analysis.
dpVL: Plasma viral loads for the recipients are shown at the time of screening prior to enrollment into the IAVI protocol C early infection study, when R880F was at Fiebig
stage III and R463F at Fiebig stage IV. The plasma viral load in R463F at Fiebig stage V was 3,980,000 copies/ml. Plasma viral loads in the donors are shown at the
timepoint when the recipients were at Fiebig stage III/IV.
doi:10.1371/journal.ppat.1004565.t001
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defect imposed by the alanine to glycine escape mutation at
position 163 in KF11 found in R880M and R880F [57,59]. Thus,
lacking the KF11 compensatory change, the minor variant
transmitted to R880F would be expected to have a reduced RC
relative to the majority of donor variants, consistent with the in
vitro experimental data above.
Longitudinal analysis of virus sequence evolution over
the entire proteome during the first year of infection
NFLG SGA was also utilized to investigate sequence evolution
in the viral quasispecies in both R880F and R463F at four time-
points up to 1 year after seroconversion. Because the VL of R880F
dropped to ,49 copies/ml at the 6-month time-point, sequences
for the 9 and 12 month samples were derived from half-genome
amplifications. A phylogenetic analysis of these sequences is shown
in highlighter plots in S3 Fig., panels A and B. For R880F, despite
control of VL, we observed the fixation of non-synonymous (NS)
mutations in pol, vif, rev, env and nef, which as we show below
reflect sites of selection by cellular immune responses. We
observed no evidence of reversion of the transmitted T cell escape
mutations in the ISW9, KF11, TW10 or QW9 epitopes during the
first year of infection. In the R463F longitudinal viral sequence
data, we observed fixation of NS mutations only in gag, tat and
nef.
Fig. 1. Plasma viral load and CD4 count in the two recipients during the first year of infection. Plasma viral load in RNA copies/ml is
plotted on a log10 scale along the left vertical axis, while the CD4 T cell count in cells/ml is plotted along the right vertical axis. Time is indicated along
the horizontal axis as days post-Fiebig Stage I/II in each recipient. The solid circles represent the longitudinal CD4 counts; the open circles represent
plasma viral load. (A) HIV-1 elite controller R880F (B) HIV-1 rapid progressor R463F.
doi:10.1371/journal.ppat.1004565.g001
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Mapping of epitopes recognized by the virus-specific T
cell response in subjects R880F and R463F
CD8 T cells play an important role in containment of virus
replication during acute and early HIV-1 infection [34,54,60,61].
Previous studies have demonstrated associations between the
specificity of the CD8 T cell response to HIV-1 and containment
of viral replication. Responses to more conserved proteins/
epitopes, escape from which often incurs a high cost to viral
fitness, are associated with better HIV control [29,62–64]. To
investigate whether there were differences in the specificity of the
CD8 T cell responses elicited during acute and early HIV-1
infection in R880F and R463F that may have contributed to their
differential infection outcomes, the epitopes in the T/F sequence
recognized by autologous T cells were mapped. For each subject, a
matrix of overlapping peptides corresponding to the amino acid
sequence of the entire T/F virus proteome was screened in IFNc
ELISPOT assays for recognition by T cells from the 6-month
time-point. Further screening was then carried out at the
enrollment time-point to check for responses to sites where there
was evidence of rapid selection for sequence changes during acute
infection, responses to which may have declined to undetectable
levels prior to the 6-month matrix screening time-point following
viral escape. Having identified epitope-containing 18-mer pep-
tides, the putative optimal epitopes recognized by T cells within
these sequences and the likely presenting HLA class I alleles were
predicted where possible (Table 2 and Table 3).
Fig. 2. Kinetics of in vitro replication of viruses recovered from the earliest-available plasma samples from R880F and R463F and
IMCs corresponding to each subject’s deduced T/F virus sequence. (A and B). Infection with virus isolates (A) or PBMC stocks derived from
IMCs (B) was performed in either pools of human CD8 depleted PBMC isolated from 3 individual donors (A) or single individuals (B), and the data is
representative of at least 3 independent experiments for each. Reverse transcriptase activity (measured in digital light units (DLU) or p24 antigen is
plotted on a log10 scale on the vertical axis against days following infection of cells in in vitro culture. HIV-1 NL4.3 is shown in (A) as a positive control
for in vitro replication. (C). Analysis of the in vitro growth rates of viruses R880 and R463 from each of 9 experiments. The growth rate of each was
calculated as the slope of increase in the logarithms of p24 or RT activity over the times when this increase was linear. A Wilcoxon signed-rank test
was used to compare the ratios obtained in the experiments. (D). A competition growth assay was performed in triplicate as described in Methods
with approximately equal input copies of R880F and R463F viral stocks. Relative amounts of each virus at days 2, 4, 6, 8, and 10 were determined by
qPCR. (E). An amino acid sequence alignment of the B*5703 Gag CD8 T cell epitopes for the R880 transmission pair is shown.
doi:10.1371/journal.ppat.1004565.g002
Viral and Host Determinants of HIV-1 Control
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Responses were detected to a total of 12 epitope-containing
regions (spanned by a single or two overlapping 18-mer peptides)
in R880F (Table 2) and 13 epitope-containing regions in R463F
(Table 3). As expected given the overlap in their HLA class I
genotype, there were several epitope-containing regions to which
responses were detected in both subjects, although around two-
thirds of the regions recognized in each individual were unique.
During the first 6 months of infection both subjects mounted T cell
responses to multiple epitopes in the relatively conserved viral
proteins Gag and Pol (7/12 of the epitope-containing regions
recognized by R880F and 8/13 of those recognized by R463F),
and both also exhibited 2 (R880F) or 3 (R463F) Env-specific
responses, 1 Nef-specific response and 2 (R880F) or 1 (R463F)
response to epitope-containing regions in other viral proteins.
Induction of a primary HIV-specific CD8 T cell response of
strikingly different breadth during acute infection in
subjects R880F and R463F
Although R880F and R463F mounted T cell responses to a
similar total number of epitopes in conserved and more variable
HIV-1 proteins within the first 6 months of infection, we
hypothesized that there may have been differences in the kinetics
of induction and/or immunodominance of responses to more
conserved viral epitopes during acute infection. We therefore
determined the relative magnitude of responses to all the epitopes
recognized in each subject (Table 2 and Table 3) at time-points
over the first year of infection using IFNc ELISpot assays (Fig. 3A
and 3B). Although responses were detected to a similar number of
epitopes (12–13) in both subjects at 6–12 months post-infection,
there was a striking difference in their initial response breadth,
with responses being detected to 7 epitopes at the earliest time-
point tested in acute infection in R880F, but to only 2 epitopes in
R463F. Furthermore, whereas the primary HIV-specific T cell
response in R880F was dominated by a response to an epitope in
Gag (Gag 85–95), with strong responses also being observed to
epitopes in Pol and Env (Fig. 3A and Table 4), the initially-
immunodominant response in R463F was directed against Tat
(Tat 33–50), with a second response to a Pol epitope (Fig. 3B and
Table 5). The initial immunodominance of a response to an
epitope in Gag, combined with the greater overall breadth of the
primary HIV-specific T cell response in R880F, may have limited
the extent of rapid viral escape and contributed to the more
effective viral control in this subject. Notably, whereas in subject
R880F the initially-immunodominant Gag 85–95 response
remained one of the most dominant responses throughout the
first year of infection, the Tat 33–50 response that was
immunodominant in primary infection in subject R463F under-
went a rapid decline in relative magnitude, consistent with a
selective reduction in antigenic stimulation due to viral escape
(Fig. 3 and Table 5). This again suggested that there could have
been differential escape from the initially-immunodominant T cell
responses in these two subjects.
Comparison of the extent and kinetics of viral escape
from the primary HIV-specific T cell response in R880F
and R463F
To assess the extent and kinetics of viral escape from the T cell
responses induced during acute HIV infection in the two
recipients, longitudinal viral sequence evolution was monitored
by NFLG SGA and sequencing (S3 Fig., panels A and B) and NS
mutations occurring in the epitope-containing regions to which the
patients’ T cell responses were directed were identified (S1 Table
and S2 Table). By 1 year post-infection, there was evidence of
some degree of selection for sequence change(s) in 7/12 of the
epitope-containing regions recognized in R880F and 8/13 of those
recognized in R463F. Hence despite their different viral loads,
extensive evolution of the viral quasispecies was able to occur in
response to T cell pressure in both subjects. The impact of the
amino acid changes selected for within epitope-containing regions
in each subject on peptide recognition by autologous T cells was
evaluated by comparing the T cell response to serial dilutions of
the index and mutant peptide sequences in IFNc ELISpot assays.
In both subjects, the majority of the mutations selected for in vivo
were found to impair or ablate peptide recognition by epitope-
specific T cells (S4 Fig., panels A and B). Mutations that did not
impair peptide recognition may also have conferred escape from T
cell responses via effects on epitope processing (not evaluated
here), suggesting that most, if not all, of the sequence changes
selected for over time in epitope-containing regions represented
emergence of T cell escape mutations. The observation that viral
evolution to escape, at least to some extent, from multiple epitope-
specific T cell responses in these two subtype A virus-infected
individuals is consistent with results from previous studies in
patients infected with subtype B and C viruses, which have shown
that viral escape from components of the host T cell response is a
hallmark of acute/early HIV-1 infection [35,54,62]. Notably,
there was evidence of escape from only 6/15 of the T cell
responses directed to epitopes in Gag and Pol, the mean entropy of
which was 0.26nats, in the two recipients, whereas 10/10 of the T
cell responses directed against epitopes in Env and other viral
proteins, the average entropy of which was 0.89nats, showed
evidence of escape by 1 year post-infection. This confirms the
importance of epitope entropy as a determinant of escape from
epitope-specific T cell responses during acute and early HIV-1
infection [35,62,65].
Although escape-conferring mutations were selected for in a
proportion of the viral quasispecies by 1 year post-infection in
many of the epitopes targeted by the T cell response in R880F and
R463F, there were marked differences in the extent and kinetics of
viral escape from the initially-immunodominant T cell responses
in these subjects. In R880F, mutations did not begin to emerge in
the Gag 85–95 epitope targeted by the initially-immunodominant
T cell response until day 73 post Fiebig I/II. Furthermore, the
mutations that occurred in the Gag 85–95 sequence did not
entirely ablate epitope recognition by patient T cells, and a high
proportion of the viral quasispecies retained the index epitope
sequence over the entire first year of infection. This suggests that
acquisition of mutations that conferred robust escape from this
response incurred a high cost to viral fitness. Likewise the Env
350–368 and Pol 969–986 sequences to which strong responses
were also observed during primary infection in R880F showed no
evidence of sequence change until 9 months post-infection and
underwent limited sequence change over the entire year of follow-
up. Although mutations conferring escape from some T cell
responses were selected for to completion (i.e. entirely replaced the
T/F virus sequence) in this subject, the responses that were
effectively escaped did not constitute major components of the
overall T cell response (Table 4 and Fig. 3A). For example, the
most rapidly-emerging escape occurred in the Nef 177–194
epitope, where escape variants completely replaced the index virus
by day 73 post Fiebig I/II (Table 4).
By contrast, in subject R463F there was rapid emergence of
effective escape mutations in the Tat 33–50 epitope recognized by
the initially-immunodominant T cell response, and these muta-
tions were represented in a majority (11/13) of the sequences at
day 19 post Fiebig I/II, with selection to completion by day 60
(Table 5 and Fig. 3). The rapid escape from a high proportion of
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the primary HIV-specific T cell response in R463F but not R880F
(S5 Fig.) likely was one of the factors contributing to the differing
efficiencies of viral control in these subjects.
Comparison of the early HIV-specific CD4 T cell response
in subjects R880F and R463F
Virus-specific CD4 T cell responses play important helper roles
in the immune response, and can also mediate effector activity that
contributes to control of viral replication. Although CD4 T cell
responses can be detected by IFNc ELISPOT assay (and it is likely
that some of the T cell responses identified in the analyses
described above were mediated by CD4 T cells), many CD4 T
cells do not produce IFNc, making other approaches more suitable
for CD4 T cell response analysis. We therefore employed a flow
cytometry based method, where responding CD4 T cells are
detected on the basis of CD154 up-regulation following antigenic
stimulation (S6 Fig., panel A), to enable comparison of the relative
magnitude of the Env- and Gag-specific CD4 T cell response in
subjects R880F and R463F at early times post-infection. As shown
in S6 Fig., panel B, R880F exhibited much higher-magnitude Gag
and Env-specific CD4 T cell responses than R463F both during
acute infection at ,3 months post-infection. The more robust
CD4 T cell response in subject R880F may have been
consequentially and/or causally related to the lower levels of
early virus replication in this subject.
Viral Env evolution and NAb activity during the first year
of infection
To investigate the added selection pressure imposed by the
humoral immune response, we examined the development of
neutralizing Abs in both R463F and R880F over the first year of
infection and correlated this with the appearance of neutralization
escape mutations within the env sequence. To quantitate the
appearance of neutralizing Ab, the env gene from the T/F virus
was used to generate pseudotyped virions for the TZM-bl cell
neutralization assay [66,67]. Within 2 months of infection both
individuals developed detectable neutralizing Ab activity against
the T/F Env, and by day 73/60 robust IC50 titers of 1:4500
(R880F) and 1:720 (R463F) were present (Fig. 4A). At this time-
point, a variety of amino acid substitutions were observed in the
variable regions of gp120 (S7 Fig., panels A and B). Over the
following 9 months additional amino acid changes occurred in
Env gp120 of both R880F and R463F. These were found in V1,
V2, V3, a2 helix, V4 and V5 regions of Env, and frequently
involved changes in both the position and number of N-linked
glycosylation sites (S7 Fig., panels A and B). These sequence
changes were consistent with a pattern of ongoing viral escape and
de novo neutralizing Ab production in both recipients (S7 Fig.,
panels A and B). Previously, the initial autologous neutralizing Ab
response in R880F was mapped to an epitope at the base of the V3
domain, and early viral escape was conferred by one of three single
amino acid substitutions in this region, indicated in red in S7 Fig.,
panel A (Murphy et al, 2013). Viral escape at later time points
involved changes in N-linked glycosylation. Thus, there was
ongoing selection of escape variants by neutralizing antibodies in
R880F, even after the VL decreased to undetectable levels.
Indeed, an analysis of neutralization of Env pseudotypes derived
from d10–d341 viruses by plasma from these same time points
showed that while contemporaneous viruses were resistant to
neutralization, the potency against the T/F Env increased
throughout the first year in R880F (Fig. 4B). Moreover, the
breadth of de novo neutralizing antibodies in R880F continued to
evolve, such that even day 341 plasma neutralized earlier Env
escape variants better than plasma from previous time points
(Fig. 4B). In R463F, at 1 year post-infection, when T cell depletion
was evident and viral loads were very high, there was still ongoing
evolution of the potency of plasma to neutralize earlier resistant
variants (Fig. 4C). Nevertheless, this ongoing antibody-mediated
selection pressure clearly was insufficient to contain viral load.
Discussion
During acute HIV-1 infection viremia increases exponentially to
a peak that can exceed 108 RNA copies/ml (although in some
subjects is substantially lower), then declines to a set-point
persisting level that is a strong predictor of subsequent disease
progression [3,13]. HIV-1 specific CD8 T cell responses start to
expand substantially as systemic viral spread occurs, with the
earliest responses reaching peak magnitude a few days after the
peak in viremia [68–70]. HIV-1 seroconversion is typically also
detected at or just after viremia reaches a maximum [71]. Previous
studies, principally focusing on subtype B and C infections, have
shown that VL and its control during this early stage of infection is
defined by multiple viral and host factors, including the T/F virus
replication phenotype, gender, age, and class I HLA alleles of the
recipient as well as host genetic markers in the donor
[2,21,25,37,40,46,47]. Both immunological and genetic evidence
indicate that viral control by CD8 T cell responses is an important
determinant of set-point viremia [23,33,60,61]. Importantly,
however, there is limited information on how the interplay, within
an individual, between viral replicative fitness and host humoral
and T cell responses might determine viral control. In this study,
we therefore investigated the basis of immune control during the
earliest stages of infection by analyzing, from both a virological
and immunological standpoint, two transmission pairs with
distinct disease trajectories in a Rwandan cohort infected by
viruses from the relatively understudied HIV-1 subtype A.
The HIV-1 transmission pairs studied were identified sufficient-
ly close to the time of transmission that, using single genome near-
full length PCR amplification, we could determine the sequence of
the single T/F virus that infected each recipient and define
immune-driven evolution across the entire proteome in the context
of the HLA class I profile of both recipient and donor. Moreover,
we could compare the T/F sequence to that of a sampling of the
donor quasispecies near to the time of infection, confirming the
genetic bottleneck that occurred during transmission. The two
extremes of HIV-1 pathogenesis observed for these newly infected
partners (R880F and R463F), developed despite the fact that they
shared 3/6 HLA-I alleles. This allowed us to probe how the
properties of the infecting virus and early immune responses
involved in virus control might contribute to the two different
outcomes.
Replication competent virus stocks, derived from Fiebig stage
III/IV plasma, and T/F IMCs for both recipients were used in
in vitro replication assays in PBMCs, which showed that the virus
Fig. 3. T cell response kinetics during acute and early HIV-1 infection. For both R880F (A) and R463F(B), individual peptide response
magnitudes in an IFNc ELISpot assay are shown as a percentage of the overall response. The insert shows the number of peptide responses detected
and the total response magnitude (SFC/106 PBMCs) at each of the time points tested. The sequences of the peptides are shown in Table 2.
doi:10.1371/journal.ppat.1004565.g003
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infecting R880F had a significantly lower RC than that derived
from R463F and that the latter rapidly outcompeted R880F in
competition assays, consistent with the .100-fold difference in
plasma VLs at Fiebig III/IV stage of infection. A likely basis for
this difference was defined by an analysis of the virus in
transmitting partner of R880F, who carried the favorable HLA
class I allele B*5703. The gag sequence of the T/F virus contained
mutations consistent with immune escape in all 4 of the previously
described B*5703 Gag epitopes. Interestingly, a majority (10/11)
of the R880M viral genomes encoded both the A163G and the
compensating S165N mutation [57,59] in the KF11 Gag epitope.
This compensatory mutation was absent in one R880M genomic
sequence and, consistent with the reduced RC observed for the T/
F virus, in the T/F virus sequence of R880F. Moreover, there was
no reversion of any of the B*5703 Gag epitope escape mutations
during the first year of infection. Thus it appears that a less
abundant, replication defective virus was transmitted from R880M
to his partner, which likely contributed to her lower Fiebig III VL.
In contrast, the T/F virus from R463F, in whom the maximum-
recorded VL was 1.526108 HIV-1 RNA copies/ml, replicated
efficiently in vitro. In an analysis of the in vitro RC of chimeric
viruses with gag genes derived from 150 acutely infecting subtype
C viruses, we showed that both lower VL and slower CD4 decline
were significantly associated with low RC viruses [18]. Moreover,
lower fitness viruses have been shown to be transmitted from
individuals carrying protective HLA alleles, and have also been
associated with elite control of VL [2,15,17,18,46,72,73]. Thus the
difference in viral RC and peak VL between R880F and R463F
may be a key contributor to the different disease trajectories in
these subjects.
Use of near full-length SGA to investigate longitudinal viral
sequences from both recipients also allowed us to define viral
genomic evolution, driven by the de novo immune response, in the
linked recipient over the first year of infection. Surprisingly, during
this period, we observed evidence for selection of mutations at only
a limited number of positions. For the controller, R880F, outside
of Env, where we showed early selection of multiple neutralization
escape mutations and evidence for T cell-driven escape at two
sites, fixation of amino acid changes was observed in Pol, Rev, Tat
and Nef. In each case the sites of mutation corresponded to
epitopes recognized by the subject’s T cell response. It is of interest
that for the most part, selection and fixation of these T cell escape
mutations in R880F occurred after VL had been suppressed to
,49 [74] copies/ml. This indicates that despite viremia being
below detectable levels, sufficient virus replication was nonetheless
occurring for escape mutations to be generated and, in the context
of pressure from the T cell response, to reach fixation in the
quasispecies. For the progressor, R463F, even fewer residues
showed evidence of immune escape outside of Env, where, in
addition to escape from neutralization, two residues at sites
targeted by T cells also escaped. Fixation of amino acid changes
occurred in Gag, Tat and Nef, which again correlated with
detection of T cell responses to these sites. The fixation of
mutations at fewer sites in the quasispecies during early infection
in R463F than in R880F, despite the much higher levels of
ongoing virus replication in the former subject, suggests that the T
cell responses in subject R463F exerted less pressure on viral
replication than those in R880F, likely as a result of a decline in
their antiviral efficacy, which both we and others have shown
occurs during early infection in subjects who do not control
viremia efficiently [75–77].
We were able to use the sequence of the T/F virus in each
recipient to construct matrices of overlapping peptides corre-
sponding to the entire autologous T/F virus proteome, which
enabled comprehensive analysis of the epitopes recognized by the
T cell responses induced in each subject during the first 6 months
of infection. The kinetics of the response to each epitope were also
analyzed. For R880F, a broad T cell response was observed even
at the earliest time of sampling, with 7 epitopes in Gag, Pol, Env
(2), Rev, Vif and Nef being recognized by the primary T cell
response. The most dominant responses at this stage were to
epitopes in Gag (Gag 85–95) and Env (Env 350–368). The former
was predicted to be restricted by HLA-Cw0602, an HLA-C allele
with relatively high expression levels, a phenotype recently
reported to be associated with good HIV-1 control, putatively as
a consequence of restriction of efficacious HIV-specific T cell
responses [78]. There was no evidence of rapid emergence of
escape mutations at either of these sites. Furthermore, although
some mutations were observed in the Gag epitope by ,3 months
post-infection they were not strongly selected for over time, and
remained a low proportion of the quasispecies even at one year
post-infection (14%). This suggests that acquisition of escape
mutations in/around this epitope in the Gag matrix domain might
result in an unacceptable loss of viral replicative fitness. Similarly,
the site targeted in Env (350–368) is very close to residues involved
in the CD4 binding site, which is critical to virus infectivity.
The primary T cell response in R463F was quite distinct, being
much narrower and targeting only two epitopes (Pol 969–986 and
Tat 33–50) at the earliest time-point tested. The more immuno-
dominant of these responses was directed against the Tat epitope,
which by day 12 post Fiebig I/II was already exhibiting evidence
of escape with 10% of the sequences mutated from that of the T/
F, and more than 90% escape on day 19. Thus, the earliest CD8 T
response in this individual was predominantly targeted at an
epitope that was easily mutated with presumably little replicative
fitness cost. Interestingly, although this Tat epitope was presented
by HLA B*1503 and thus might have been expected to be a
common response in both recipients, it was not detectably targeted
by R880F, likely because existing mutations in this peptide
(FLNKGLGISY vs FQHKGLGISY) abrogated HLA binding and
precluded recognition. Thus, the acquisition by R880F of a T/F
virus with a mutated Tat protein may have spared early targeting
of an easily escaped epitope. The initially narrow response in
R463F broadened over the next few months such that by 6 months
post-infection a total of 13 epitopes were recognized, with
dominant responses to epitopes in Gag (Gag 132–149) and the
original Pol epitope, but despite this VL remained .300,000
copies/ml. Notably, even when the response increased in breadth,
R463F did not recognize the Gag 85–95 epitope targeted by the
most immunodominant T cell response in R880F despite the fact
that, like the Tat 33–50 epitope, this was predicted to be presented
by a HLA allele shared by both recipients. Again, the viruses
transmitted to the two recipients showed sequence differences
within and around this epitope (LYCVHQRIEVK in R880F and
LYCVHRKIDVK in R463F) that may have precluded epitope
presentation and/or recognition in R463F. These observations
underline the importance of the T/F virus sequence in shaping the
specificity of the host T cell response: despite the overlap in their
class I genotypes, the initially-immunodominant T cell responses
in R880F and R463F were entirely different, with R463F targeting
a rapidly-mutating Tat epitope that was not conserved in R880F’s
T/F virus sequence and a Pol epitope that was recognized by
R880F, but was subdominant in R880F’s response to a low
entropy Gag epitope that was not conserved in R463F’s T/F virus
sequence.
Previous studies [79] have failed to observe an association
between the breadth of the CTL response in early chronic
infection and set-point VL, and if we consider responses at 3–6
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months post-infection, that is also the case here. However, this is
not so at acute time-points (days 17 and 19 post Fiebig I/II) when
major differences in the breadth of the response were observed in
these two subjects who exhibited disparate abilities to control virus
replication. The limited epitope breadth of the primary HIV-
specific T cell response in R463F is not unusual: we and others
have found that initial expansion of responses to only a limited
number of viral epitopes, followed by delayed expansion of
additional responses, occurs in a high proportion of HIV-1-
seroconverting subjects [62,70]. In a previous study where we
conducted a proteome-wide analysis of the kinetics of epitope-
specific T cell response expansion in 21 subtype B acutely-infected
individuals, responses were observed to a median of only 2
epitopes at the earliest time-point tested (between 5 and 32 days
following onset of symptoms, which typically develop a few days
after the Fiebig I/II transition) [70]. In these subjects, we did not
observe a correlation between the response breadth at the earliest
time-point tested and the subsequent set-point VL. This may have
been because many of the subjects in this cohort established
moderate-high persisting viral loads or because not all subjects
studied were sampled sufficiently early to enable accurate
assessment of the initial response breadth; and/or may indicate
that response breadth is not itself the most critical determinant of
the efficiency of viral control. Instead, the extent and kinetics of
viral escape from the earliest epitope-specific CD8 responses may
be the key determinant of the efficiency of early HIV-1 control,
with response breadth influencing viral control indirectly via its
effect on the efficiency of escape [80,81].
The primary HIV-specific T cell response in R880F was not
only considerably broader than that in R463F, but its most
dominant components also targeted epitopes in sites where
acquisition of escape-conferring mutations was likely to incur
significant costs to viral fitness, and where escape mutations
emerged with delayed kinetics and were not selected for to
completion in the viral quasispecies during the first year of
infection. By contrast, the more dominant of the two responses
initially induced in R463F targeted a rapidly-mutating epitope in
Tat, which was already mutated in the transmitted founder virus
in R880F in whom no T-cell response to it was detected. Thus, in
this subject, the immune system was not ‘‘distracted’’ by an
epitope that could rapidly escape. This may have been a critical
component of control, since during acute SIV infection escape
from immunodominant Mamu-B*0801-restricted CD8 T cell
responses was found to differentiate Mamu-B*0801+ macaques
that subsequently underwent rapid disease progression from those
controlling viral replication [82]. Moreover, the association of
HLA-B*2705 with good HIV-1 control is thought to be largely
attributable to early targeting of a highly conserved Gag epitope
by the most immunodominant HLA-B*2705-restricted T cell
response, escape from which is typically not observed until many
years post-infection [31]. There is also strong evidence that early
targeting of responses to conserved epitopes where escape can
occur, but only at a high cost to viral fitness, is associated with
good HIV-1 control [26,29,83]. As epitope entropy is an
important determinant of the rate of emergence of escape
mutations during acute HIV-1 infection [62,65], the beneficial
effect of targeting conserved epitopes may be due in part to the
delayed kinetics with which the most immunodominant compo-
nents of the primary T cell response are escaped in acute infection.
Both R463F and R880F exhibited responses to a similar
number of epitopes by ,6 months post-infection. As both subjects
were capable of mounting T cell responses to a similar number of
viral epitopes, it is unclear why the initial T cell response in R463F
was much narrower than that in R880F. The difference observed
in the magnitude of the HIV-specific CD4 T cell response in these
subjects is unlikely to explain this, as the priming and initial
expansion of CD8 T cells does not require help from CD4 T cells
[74]. Instead, it is more likely to be have been due to differences in
dendritic cell (DC)-mediated T cell priming. We have found that
apoptotic microparticles, which reach high concentrations in the
circulation during acute HIV-1 infection as extensive destruction
of CD4 T cells occurs [84], inhibit DC functions, impairing the
ability of DCs to produce IL-12 and prime T cell responses [85].
As the magnitude and dynamics of the increase in circulating levels
of apoptotic microparticles parallel those of viremia, DC functions
may be rapidly and severely impaired in patients such as R463F
who experience a high-magnitude acute viremic burst, resulting in
initial priming of T cell responses to relatively few epitopes, with
responses of additional specificities being primed only after viremia
declines and DCs are replenished. By contrast, in a patient such as
R880F, infected with a less fit virus, and where peak viremia is
lower, DC functions may be less severely compromised and/or a
greater breadth of T cell responses may be initiated prior to
impairment of DC functions, resulting in expansion of a primary T
cell response of greater epitope breadth. The fitness of the
transmitted virus may therefore impact on set-point viremia both
directly and also indirectly, by influencing the breadth of the
primary HIV-specific CD8 T cell response and subsequent
efficiency of T cell control of viremia.
The role of neutralizing Ab (NAb) in elite control at early phases
of infection is not understood, and how it might influence the
control of HIV-1 infection and disease progression remains
controversial [86]. Early studies focused on HIV-1 LTNP showed
that in some cases increased NAb breadth was associated with
reduced disease progression [4,87–89], while in other studies NAb
were found to be lower in the EC/LTNP subgroup in comparison
to chronic progressors [90–93]. In this study, we observed a robust
autologous NAb response to the T/F virus in both R880F and
R463F, and a more detailed analysis of the development of the Ab
response in R880F demonstrated multiple pathways of viral escape
followed by de novo neutralization [94]. Previous studies have
demonstrated that early NAb escape involves single amino acid
substitutions, insertion and deletion of amino acids in the variable
loops of gp120, and shifts in the positions of glycosylation sites in
gp120 [94–104]. In the current study, we observed no significant
differences in the magnitude or kinetics of autologous NAb during
the first year infection of R880F and R463F. In the former, two
single mutations identified at day 73 post Fiebig I/II, one just
upstream of the V3 loop (I295R) and one in the a2Helix (E338K)
regions, were responsible for the earliest NAb escape, and
pinpointed the first NAb epitope targeted in this individual [94].
Fixation of neutralization escape mutations provides evidence for
Fig. 4. Longitudinal autologous neutralizing antibody IC50 titer during the first year of infection. (A). The IC50 neutralizing titer (plasma
dilution) against the T/F virus Env-pseudotyped HIV-1 derived from either R463F or R880F is plotted on the vertical axis on a log scale. R463F is
depicted by open triangles; R880F is depicted by open squares. These experiments were replicated independently at least 3 times. (B). Heat map
showing autologous neutralizing Ab activity versus Envs sampled during the first year of infection. Upper Panel R880F, Lower Panel R463F. Plasma
sample dates (post-Fiebig I/II) are shown across the top, and Env clones used as pseudotypes from each time point are shown on the left. Green
indicates IC50 Ab titers less than 1:100; yellow indicates IC50s between 1:100–1:1000; orange indicates IC50s between 1:1000–1:10,000; red indicates
IC50s.1:10,000.
doi:10.1371/journal.ppat.1004565.g004
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ongoing selective pressure on the virus with replacement of a
susceptible population by one resistant to neutralization, and this
was observed in the a2 helix region of R880F at day 157. Glycan
shifts and additions were also observed in R880F that also
conferred escape at later time points. Fixation of new mutations
longitudinally in Env and an evolving Ab response even after VL is
below detection is further evidence of ongoing virus replication
and continued pressure on the virus that presumably could
contribute to continued immunological containment.
In R463F early NAb responses appeared to be focused on the
V4 region of Env, rather than the a2-helix, with half of the
amplicons (9/18) at this time-point exhibiting the addition of a
glycosylation site in this region, which was associated with
increased virus neutralization resistance. In contrast to R880F, a
more diverse population of Envs developed over time with deletion
and insertion mutations in V4 and V1 observed at the d179 and
d248 time points. The selection of these more drastic mutations
may reflect the higher RC of the virus and the generation of more
diverse errors, consistent with lack of control of VL.
Together, the results from this study highlight the combined
roles of the fitness of the T/F virus and the efficiency of viral
control by host T cell responses in determining the outcome of
HIV-1 infection. Whilst the relative contributions of the two
cannot be precisely determined, our findings suggest that the
replicative capacity of the transmitted virus may be particularly
important. T/F virus fitness may not only play a direct role in
determining the magnitude of the acute viral burst and subsequent
levels of viral replication, but may also have a simultaneous impact
on the efficiency of host immune control of viral replication,
influencing early T cell response breadth and hence patterns of
viral escape, and dictating the availability of CD4 T cell help to
sustain T cell effector functions over time. In line with this, it is
notable that genetic studies have found that only ,22% of the
variation in set point viremia can be explained by common
polymorphisms in/around the MHC class I locus [23,24]. Whilst
this may reflect an important role for rare host genetic variants in
dictating levels of early virus replication, it is tempting to speculate
that the nature of the infecting virus may be a key determinant of
HIV-1 infection outcome.
For HIV-1 vaccine development, understanding the complex
interactions between virus and host that result in HIV-1 elite
control at the earliest phase of infection is crucial. This study has
provided a unique opportunity to investigate in a comparative
fashion the viral phenotype and host adaptive immune responses
in two individuals with highly disparate disease outcomes during
the earliest phase of infection. Overall these results suggest that in
the rapid progressor, infection by a robustly replicating virus,
coupled with a narrow T cell response that was in part focused on
a rapidly mutating epitope precluded viral control. In contrast, in
the elite controller, a combination of infection by a less replication
competent virus, which may have spared the CD4 repertoire, and
a diverse T cell response to epitopes that remained stable over the
first few months of infection, implying subsequent escape may
have incurred a higher cost to viral fitness, allowed near complete
suppression of virus replication. It will be important to extend
similar, comprehensive studies to a larger number of infected
individuals in future, to determine the generality of the observa-
tions reported here. However, these findings highlight the
importance of early viral replication in determining subsequent
viral control, emphasizing the need for vaccines to elicit rapidly
acting responses that will constrain virus replication in the earliest
stages of infection. They also underscore the importance of the
earliest CD8 T cell response targeting regions of the virus
proteome that cannot mutate without a high fitness cost, further
emphasizing the need for the development of vaccines that elicit a
breadth of T cell responses to conserved viral epitopes.
Methods
Ethics statement
This study was approved by the Rwanda National Ethics
Committee in Kigali, Rwanda and by the Emory University
Institutional Review Board. All individuals enrolled into this
cohort provided written informed consent.
Study subjects
The two HIV-1 subtype A transmission pairs investigated in this
study were enrolled in the heterosexual discordant couple cohort
at Projet San Francisco in Kigali, Rwanda. The HIV-1
serodiscordant couples received counseling and testing on a
monthly basis prior to the negative partner becoming HIV-1
positive. The recipients were enrolled in the International AIDS
Vaccine Initiative (IAVI) Protocol C early-infection cohort. The
epidemiological linkage status for each transmission pair was
defined by phylogenetic analyses of HIV-1 gp41 sequences
between cohabiting partners [105]. Both recipients were ART
naı¨ve during this study period. Infection in R880F was detected at
Fiebig stage III, when plasma samples were collected; and PBMC
were first cryopreserved 7 days later following seroconversion to
Fiebig stage IV. Infection in R463F was detected at Fiebig stage
IV, when plasma samples were collected; PBMC were first
cryopreserved 7 days later at Fiebig stage V. Days post Fiebig stage
I to stage II were calculated for each sample time-point based on
previously reported time intervals [71].
Plasma viral RNA/genomic DNA extraction and cDNA
synthesis
Plasma viral RNA and genomic DNA were isolated using the
QIAamp RNA and DNA mini kits (Qiagen, Valencia, CA), and
cDNA synthesis was carried out using Superscript III (Invitrogen).
For plasma samples with VL,50 copies/ml, 1 ml of plasma was
ultracentrifuged for 2 h at 114,000 g, and the viral pellet was
resuspended in 140 ml of residual plasma before the extraction.
Reverse transcription of extracted RNA was carried out in two
stages: in the 1st stage incubation was at 50uC with 5 U of reverse
transcriptase (RT) for 1 hour with 0.5 mM of each dNTP, 5 mM
DTT, 2 U/ml RNaseOUT (RNase inhibitor), and 0.25 mM
antisense primer; the 2nd stage involved incubation at 55uC with
an additional 5 U of RT for 2 hours. Synthesis was initiated by
reverse primer: 59-ACTACTTAGAGCACTCAAGG-
CAAGCTTTATTG-39 [52], and terminated by incubating at
70uC for 15 min, followed by 20 min at 37uC with 1 ml RNase H.
The cDNA was used immediately for PCR amplification.
Near full-length HIV-1 genome amplification
For single genome PCR amplification, the cDNA was serially
diluted and the dilution yielding approximately 30% NFLG PCR
positive reactions was used [51,106] to ensure a majority of the
amplicons were derived from a single viral cDNA molecule. The
first round PCR primers used for this nested PCR reactions were:
sense primer 1.U5Cc - HXB2 positions 538–571 –
59-CCTTGAGTGCTCTAAGTAGTGTGTGCCCGTCT-
GT-39,
and antisense primer 1.3939PlCb at HXB2 positions 9611–9642 –
59-ACTACTTAGAGCACTCAAGGCAAGCTTTATTG-39;
2nd round primers were:
sense primer 2.U5Cd at HXB2 positions 552–581
59-AGTAGTGTGTGCCCGTCTGTTGTGTGACTC-39
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and antisense primer 2.3939plCb at HXB2 positions 9604–9636 –
59-TAGAGCACTCAAGGCAAGCTTTATTGAGG-39 [52].
PCR reactions were carried out by using the Expand Long
Template PCR System, (Roche, cat. no. 11 681 842 001) as
recommended by the manufacturer with 0.35 mM dNTP (10 mM
each), 0.2 mm sense and antisense primers and 2 U of Expand Long
Template DNA polymerase. After an initial 2 min at 94uC, the first
10 cycles were 94uC 15 sec denaturation, 60uC 30 sec annealing
and 68uC 9 min extension; followed by 20 cycles of 94uC 15 sec,
60uC 30 sec and 60uC 9 minutes+20 sec/cycle for the extension
step. The final PCR product was incubated at 72uC for 20 minutes
prior storage at 4uC. All the procedures were performed under strict
clean-room procedures to prevent contamination.
Sequencing and viral sequence analysis
The entire ,9 kb PCR fragments were sequenced using cycle-
sequencing with BigDye terminator chemistry and protocols
provided by Applied Biosystems and then analyzed using an ABI
3730xl genetic analyzer (Applied Biosystems) at the University of
Alabama at Birmingham Sequencing core. All sequences were
aligned using the Gene Cutter tool (Los Alamos National
Laboratory - http://www.hiv.lanl.gov/content/sequence/
GENE_CUTTER/cutter.html). Sequences were analyzed phylo-
genetically using Geneious software (Biomatters, Aukland, NZ) and
the highlighter tool (http://www.hiv.lanl.gov/content/sequence/
HIGHLIGHT/highlighter_top.html). Entropy analyses were per-
formed using the LANL Entropy tool (http://www.hiv.lanl.gov/
content/sequence/ENTROPY/entropy.html). These analyses al-
lowed us to define the T/F virus sequence and to visualize sequence
polymorphisms and evolution in longitudinal sequence data in
order to assess potential T cell and neutralizing Ab escape mutations
and compensatory mutations.
Acute infection virus isolation and T/F IMC generation
Virus stocks were isolated from p24 positive patient plasma
cryopreserved from each subject at the earliest available timepoint
in infection (Fiebig stage III (R880F) or IV (R463F)). A total of
,506106 PBMCs from a mix of 3 HIV-seronegative donors were
used to generate CD8-depleted pools of activated PBMC. Cells
were stimulated by incubation for 72 hours at 37uC in 5% CO2 in
RPMI medium with 20% FBS containing 20 U/ml IL-2, 50 ng/
ml OKT3 anti-CD3 Ab (R&D Systems, Minneapolis, MN) and
100 ng/ml anti-CD28 Ab (eBioscience, San Diego, CA). CD8
depletion was performed using MACS LD columns (MIltenyi
Biotec) as per protocol. A total of 1 ml plasma was mixed with
50 ml anti-CD44 beads (MACS molecular), and incubated at 4uC
for 30 minutes with agitation. The CD44/virus combination was
mixed with the CD8-depleted PBMC (206106 cells) in 4 ml of
RPMI containing 10% FBS and spinoculated at 25uC for 2 h at
1200 g. The cell pellet was resuspended in 15 ml RPMI with 20%
FBS and 20 U/ml IL-2 and incubated for 48 hrs at 37uC, 5%
CO2. The infection culture was expanded by spinoculating the
initially infected cells with an additional 206106 cells for 2 hours
at 1200 g. Virus was harvested sequentially on days 5, 7, 9, 11 and
13 and titrated on TZM-bl cells as described previously [50,66].
To confirm the identity of the virus stocks, 5 NFLG were PCR
amplified from d9 stocks and sequenced from both. The consensus
sequence derived from these was confirmed to be identical to that
of the NFLG amplified at these time-points from the patient
plasma. IMCs corresponding to the deduced T/F virus sequence
of each recipient were generated and infectious virus was
recovered by transfection of 293T cells as previously described
[56]. PBMC-derived virus stocks were then generated from the
293T cell supernatants.
In vitro replication capacity assay
For studies with acute virus derived stocks, a total of 56105 CD8
depleted PBMCs were infected at an MOI of 0.01 in a 96-well plate,
in triplicate. The plate was incubated at 37uC for 3 hours, then
centrifuged at 2000 RPM for 5 minutes. A total of 150 ml of the
media was removed and replaced with fresh RPMI with 10% FBS
to remove unbound virus, and this wash step was repeated 4 times.
The resuspended cell pellets were then transferred to 24-well plates,
with 1 ml RPMI with 15% FBS, 20 U/ml IL-2. The plate was
incubated at 37uC, 5% CO2, and 0.5 ml supernatant was harvested
and replaced with fresh medium on days 0, 2, 4, 6, and 10. Virus
spread through the culture was quantitated using a reverse
transcriptase assay as described recently [18].
For studies of IMC derived virus, 293T cells were transfected as
described previously [56], and the resulting virus was added to 0.5
million CD4 T cells derived from individual donors at various
multiplicities of infection (0.02, 0.1, 0.5). After a 2 hour incubation the
cells were washed 3 times, then virus production was assessed by
removing 0.06 ml culture medium at the indicated days post-infection
(culture medium was not replenished) and quantitating p24 levels.
Competition replication assay
For the competition replication assay, input virus concentra-
tions were adjusted to have equal and 1:4 ratios of R463 and
R880 RNA copies as assessed using the qPCR quantitation
described below. Anti-CD3/anti-CD28 activated, CD8+ T cell-
depleted, PBMCs were infected at a total MOI of 0.01 in
triplicate as described above but in 24-well plates, and 0.5 ml
samples were removed on days 2, 4, 6, 8 and 10. RNA was
extracted, using Qiagen mini viral RNA columns (Qiagen,
Valencia, CA) from 140 ml of clarified culture supernatant for
each sample and 1/5 of the eluted RNA was used for cDNA
synthesis, using superscript III, as described by the manufac-
turer. Samples were diluted in nuclease-free water and analyzed
simultaneously by quantitative real-time PCR (qPCR) for each
virus.
HIV Clade A integrase primer and probe sequences are:
Fwd 59-GTTATYCCAGCAGARACAGG-39,
Rev 59-TGACTTTGRGGATTGTAGGG-39,
R880 probe 59-GCCTGTTGGTGGGCCGGC-39.
R463 probe 59-GCCTGTTGGTGGGCAAAT-39.
qPCRs were performed using the Taqman Universal master
mix (Life Technologies), 0.2 mM of each primer, and 0.125 mM of
probe. All assays were performed on the ABI 7500 systems (Life
Technologies). RNA copy numbers were calculated from standard
curves derived from known concentrations of linearized plasmids
encoding the respective integrase region, and relative proportions
of each virus calculated and graphed.
Statistical analysis
To compare the in vitro growth rates of viruses R880 and
R463, the data from each of 9 experiments was used to
calculate the ratio of the growth rates of R463 to R880. The
growth rate of each was calculated as the slope of increase in
the logarithms of p24 or RT activity over the times when this
increase was linear. By calculating the ratios, which lack units,
the data from both types of experiment can be used together.
The assumption was made that experiments with different
MOI and/or different donor PBMC provide independent
estimates of the growth rates. A Wilcoxon signed-rank test was
used to compare the ratios obtained in the experiments, with
the null hypothesis that both viruses replicated at the same
rate, i.e. this ratio is 1.
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Synthetic peptides
18-mer peptides overlapping by 10 amino acids were synthesized
(Sigma- Aldrich, UK) to match the sequence of the entire proteome
of the founder viruses from R880F and R463F. Approximately 400
sequence-matched peptides for each patient were arranged into 126
pools in a matrix format using the Peptide Portal program (Statistical
Center for HIV/AIDS Research and Prevention, US) adapting code
from the Deconvolute this! program [107]. Each peptide was
repeated three times in the matrix peptide plate.
For the fine-mapping of responses towards overlapping 18mers,
shorter peptides spanning previously described HLA-matched
optimal CD8 T cell epitopes as listed on the LANL database
(http://www.hiv.lanl.gov/content/index) and predicted CD8 T
cell epitopes using the syfpeithi database (http://www.syfpeithi.
de/) and/or NetMHC 3.2 Server (http://www.cbs.dtu.dk/
services/NetMHC/) were generated (Sigma- Aldrich, UK).
Mapping of the HIV-specific T cell response
HIV-specific T cell responses were mapped by IFNc ELISpot
assay using a peptide matrix screening approach as described
previously [70]. Briefly, cryopreserved patient PBMC from 6
months after enrollment were tested by IFNc ELISpot assay
(Mabtech, Sweden) for responses to a matrix of peptide pools (each
pool containing up to 10 subject-specific peptides, each at a final
concentration of 1025 M) corresponding to the autologous T/F
virus sequence. From the matrix screening a ranked list of potential
epitope-containing peptides was deduced using the Peptide Portal
program (Statistical Center for HIV/AIDS Research and Preven-
tion, US) adapting code from the Deconvolute this! program [108].
Putative epitope-containing peptides were retested individually at
1025 M in second round assays using PBMC from 3 and 9 months
after enrollment. Peptides stimulating responses measuring .36
background counts and .50 IFNc spot-forming cells per million
PBMC were considered positive in these assays. To enable
identification of any responses that were rapidly escaped during
acute infection and had declined in magnitude to below the assay
cut-off by the 6-month matrix screening time-point, peptides
spanning all sites where rapid selection for sequence change was
observed were also screened for recognition by PBMC from the
enrollment time-point. Where possible further fine-mapping of
optimal epitopes within responding overlapping 18mers were
performed using smaller peptides spanning known or predicted
HLA class I-restricted epitopes (final concentration 1025 M).
Measurement of the functional avidity of T cell responses
The functional avidity of T cell responses at sequential time-
points during the first year of HIV infection was determined by
peptide-titrated IFNc ELISpot assay. Index sequence (autologous
T/F sequence) peptides were titrated (either as responding 18mer
and/or fine-mapped optimal peptide) at final concentrations
ranging from 1025 M and 1028 M in duplicate against a constant
number of PBMC (1.5–26105/well). The functional avidity was
determined as the peptide concentration required to elicit half of
the maximal IFNc response in the assay.
Analysis of effect of intra-epitopic sequence variation on
T cell recognition (escape analysis)
Patient PBMC (1.5–26105/well) were stimulated with log-fold
titrations of either index or variant sequence peptide(s) in IFNc
ELISpot assays. A variant peptide was deemed an escape variant if its
half-maximal stimulatory concentration was at least 10-fold higher
than that of the index sequence peptide. Average epitope entropy
calculations for the CD8 T cell targets were based on HIV subtype A,
B and C sequences listed on the LANL database (http://www.hiv.
lanl.gov/content/index) and, where available, published subtype A
sequences [109]. Calculations were performed as previously
described [62].
Analysis of HIV-specific CD4 T cell responses
HIV-specific CD4 T cell responses were analyzed by measuring
the proportion of CD4 T cells up-regulating CD154 in response to
stimulation with viral peptide pools using flow cytometry. Cryo-
preserved PBMC from R880F and R463F were thawed and rested
in complete R10 medium (RPMI 1640 supplemented with 10%
fetal bovine serum and penicillin/streptomycin) with benzoase for
2 h at 37uC, 5% CO2. Rested PBMC were then incubated in R10
medium containing 10 mg/ml GolgiPlug, 0.7 mg/ml GolgiStop,
1 mg/ml anti-human CD28 antibody and 1 mg/ml of anti-human
CD49d antibody (BD Bioscience) at 1–26106/well in a 96-well V-
bottomed plate. Cells were either left unstimulated, or stimulated
with pools of overlapping peptides (2 mg/ml) corresponding to the
autologous T/F virus Gag, N-terminal half of Env (Env1) or C-
terminal half of Env (Env 2) sequence, or Staphylococcal
Enterotoxin B (SEB, 1 mg/ml) as a positive control. The plate was
incubated for 6 hours at 37uC, 5% CO2. After stimulation the cells
were washed once with PBS and then stained with CD4-PE (Dako)
for 10 min at room temperature (RT). The cells were then washed
again with PBS, and then were stained with amine dye Aqua
(Invitrogen) for 10 min at RT. The cells were then fixed with
Cytofix/Cytoperm (BD Bioscience) for 15 min at RT, and washed
once in PBS and once in permeabilisation buffer (BD Bioscience).
They were then intracellularly stained with a CD154-FITC
antibody (BD Bioscience) diluted in permeabilisation buffer for
30 min at RT. Finally, the cells were washed twice with
permeabilisation buffer and then fixed with 4% paraformaldehyde
solution. Samples were acquired on a CYAN flow cytometer (Dako)
and were analysed using FlowJo (Treestar 8.7).
Cloning of env genes from R880F and R463F and
antibody neutralization assays
The SGA PCR amplification and cloning methods for obtaining
HIV-1 env genes from virus present in plasma samples have been
described elsewhere [94,99,102]. Briefly, full-length Env gp160
coding regions (plus Rev, Vpu, and partial Nef) were cloned into
the CMV promoter-driven expression plasmid pcDNA3.1/V5-
His-TOPO (Invitrogen) and a biological function screen for each
clone was performed through generation of pseudoviruses
following co-transfection with an Env-deficient subtype B proviral
plasmid (pSG3Denv) in 293T cells using FuGENE HD (Promega).
The virus titers were defined by infecting TZM-bl cells, and the
neutralization assay was performed as described previously [50].
In short, serial diluted heat-inactivated R880F/R463F plasma
samples were assayed for neutralization potential against the Env
pseudotyped viruses in the TZM-bl cell line, with luciferase
activity as the ultimate readout, as described previously [102].
Supporting Information
S1 Fig. Phylogenetic analysis of near full-length se-
quences of R463 and R880 transmission pairs in a
neighbor-joining tree. Sequences from the donor are shown in
green; recipient sequences are shown in blue; reference sequences
are shown in black. The R463F sequences were determined at day
12 post-Fiebig I/II, when the subject was at Fiebig stage IV, and
the R880F sequences were determined at day 10 post-Fiebig I/II,
when the subject was at Fiebig stage III. The sequences from both
donors (R463M and R880M) were determined at the time-point
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when their linked transmission partners were at Fiebig stage IV
and III respectively. The T/F virus population of both
transmission pairs is derived from a single branch emanating
from the donor sequences, confirming that a single variant from
the donor population established infection. The scale represents
the fractional pair-wise horizontal distance between sequences.
Asterisks indicate bootstrap values of 90% or greater.
(PDF)
S2 Fig. qPCR competition replication assay for
R880FVS and R463FVS. Input virus concentrations were
adjusted to a 1:4 ratio of R463 and R880 RNA copies as assessed
using qPCR quantitation described in Methods. Samples were
removed on days 2, 4, 6, 8 and 10, and the relative percentage of
each virus (genome equivalents) in the culture supernatants
determined following qPCR quantitation.
(PDF)
S3 Fig. Highlighter plots of synonymous (green tick
marks) and non-synonymous (red tick marks) changes
over time from the consensus T/F virus near full-length
sequence for (A) R880F and (B) R463F. Sequence time points
are indicated to the right, and are differentiated by shading. Gray
bars indicate deletions in the amplified sequence. Where half-
genome-length sequences were determined, the breakpoint
between independent sequences is indicated by a slash.
(PDF)
S4 Fig. Investigation into viral escape in T cell epitopes
recognized by individuals R880F (A) and R463F (B). Serial
dilutions of the indicated index sequence peptides (solid lines) and
variants thereof containing amino acid changes selected for in the in
vivo patient quasispecies (dotted lines) were tested for recognition by
recipient PBMC in IFNc ELISpot assays. The y-axis of each graph
shows the magnitude of the response (spot-forming cells/106 PBMC)
detected to the peptide concentrations indicated on the x-axis (mM).
(PDF)
S5 Fig. Escape from early immunodominant epitopes in
individuals R880F andR463F.At the indicated time-points (days
post-Fiebig I/II), the % of the primary HIV-specific T cell response
that had been escaped was calculated by determining the % of the
viral quasispecies that had undergone escape from the response to
each epitope recognized by the primary T cell response (data in S1,
S2 Tables, summarized in Table 3) and multiplying by the relative
magnitude of the response concerned within the subject’s primary
HIV-specific T cell response (Table 3), then summing these values.
(PDF)
S6 Fig. Gag and Env-specific CD4+ T cell responses in
subjects R880F and R463F. Responses were analyzed at
timepoints in acute and early infection, assessed by analysis of
CD154 up-regulation in response to stimulation with autologous
virus sequence-based peptide pools. (A) Dotplots illustrating the
gating strategy for identification of antigen-responsive CD4+ T
cells. Data from PBMCs cryopreserved from subject R880F at
D73 post-Fiebig stage I/II stimulated with medium only or Env
peptide pool 2 is shown. (B) Magnitude of the CD4+ T cell
response (% CD4+ T cells up-regulating CD154) to Gag and Env
peptide pools in subjects R880F and R463F at the indicated
timepoints (days post-Fiebig stage I/II).
(PDF)
S7 Fig. Amino acid alignments for variable regions in
Env gp120 over the first year of infection for (A) R880F
and (B) R463F. Sequences were compared to the T/F consensus
sequence for each SC at the top of the alignments. Dots indicated
that the residue was conserved, while dashes indicate a deletion/
insertion. Amino acid substitutions from consensus are indicated.
Gray stripes depict sites where mutations resulted in loss of a
putative N-linked glycosylation motif (NxS/T); yellow stripes
indicate the addition of putative N-linked glycosylation sites; cyan
highlights in the consensus sequence identify stable N-linked
glycosylation sites.
(PDF)
S1 Table Longitudinal sequence analysis of epitopes in
virus isolated from individual R880F.
(PDF)
S2 Table Longitudinal sequence analysis of epitopes in
virus isolated from individual R463F.
(PDF)
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